Comparison · NCT04223193-7d4acca4
Tavapadon vs Placebo: Percentage of Responders With Much Improved or Very Much Improved on Participant Global Impression of Change (PGIC)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Tavapadon vs Placebo: Percentage of Responders With Much Improved or Very Much Improved on Participant Global Impression of Change (PGIC). Trial comparisons, record NCT04223193-7d4acca4. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04223193-7d4acca4
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.465 | 0.37 | 0.562 | wilson | |
| Risk in group 2 | 0.187 | 0.13 | 0.261 | wilson | |
| Risk difference, group 1 minus group 2 | 0.278 | 0.157 | 0.391 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 2.49 | 1.65 | 3.76 | log | |
| Odds ratio, group 1 over group 2 | 3.78 | 2.1 | 6.81 | log | |
| Number needed to treat, for one more participant with the outcome on Tavapadon than on Placebo | 3.6 | 2.56 | 6.35 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Tavapadon | Participants received Tavapadon 5 mg to 15 mg tablet QD orally for 27 weeks. | 46 | 99 | OG001 |
| Group 2 | Placebo | Participants received placebo matching to Tavapadon tablet once daily (QD) orally for 27 weeks. | 25 | 134 | OG000 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Percentage of Responders With Much Improved or Very Much Improved on Participant Global Impression of Change (PGIC)
- Description
The Patient Global Impression of Change (PGIC) is a 7-point response scale. The participant response to the question, Compared to your condition at the beginning of treatment, how much has your condition changed? was assessed.~Scores ranged from 1-7 on a scale of 1 (very much improved) to 7 (very much worse). Higher values represent a worse outcome.
- Time frame
- Week 26
- Population
- mITT Population includes subjects who receive at least 1 dose of study drug and have both a baseline and at least 1 postbaseline PGIC assessment, and had available data for analysis.
Source ClinicalTrials.gov
Trial
- Title
- Flexible-Dose Trial in Early Parkinson's Disease (PD)
- NCT number
- NCT04223193
- Phases
- PHASE3
- Conditions
- Parkinson Disease
- Interventions
- Tavapadon, Placebo
- Lead sponsor
- AbbVie
- Results first posted
- 2025-11-21
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04223193?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04223193-7d4acca4